卵巢癌复发：“铂耐药的定义是否会因PARP抑制剂和其他干预治疗而改变？”
Ovarian cancer recurrence: "is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?".
作者信息
Pejovic Tanja, Fitch Katherine, Mills Gordon
机构信息
Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, OR 97239, USA.
出版信息
Cancer Drug Resist. 2022 Jun 1;5(2):451-458. doi: 10.20517/cdr.2021.138. eCollection 2022.
Abstract
PolyADP ribose polymerase inhibitors (PARPi) have transformed the treatment of ovarian cancer. Particularly in high-grade serous ovarian cancer (HGSOC), a disease characterized by homologous recombination deficiency (HRD), PARPi have had a rapid and profound impact on the disease course, as well as biologic and biomarker definitions of HGSOC, thereby creating a paradigm shift in the approach to treatment. In this review, we discuss the role of PARPi in the maintenance treatment of HGSOC, its effect on platinum sensitivity, and cross-resistance between platinum and PARP inhibitors.
摘要
聚（ADP - 核糖）聚合酶抑制剂（PARPi）已经改变了卵巢癌的治疗方式。特别是在高级别浆液性卵巢癌（HGSOC）中，这种疾病以同源重组缺陷（HRD）为特征，PARPi对疾病进程以及HGSOC的生物学和生物标志物定义产生了迅速而深远的影响，从而在治疗方法上引发了范式转变。在本综述中，我们讨论了PARPi在HGSOC维持治疗中的作用、其对铂敏感性的影响以及铂和PARP抑制剂之间的交叉耐药性。
相似文献
1
Ovarian cancer recurrence: "is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?".
Cancer Drug Resist. 2022 Jun 1;5(2):451-458. doi: 10.20517/cdr.2021.138. eCollection 2022.
2
Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Mol Carcinog. 2019 Oct;58(10):1770-1782. doi: 10.1002/mc.23064. Epub 2019 Jun 10.
3
Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
J Transl Med. 2020 Nov 19;18(1):439. doi: 10.1186/s12967-020-02613-4.
4
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Cancer Chemother Pharmacol. 2018 Apr;81(4):647-658. doi: 10.1007/s00280-018-3532-9. Epub 2018 Feb 20.
5
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Expert Opin Emerg Drugs. 2020 Jun;25(2):165-188. doi: 10.1080/14728214.2020.1773791. Epub 2020 Jun 22.
6
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer. 2021 Jul 15;127(14):2432-2441. doi: 10.1002/cncr.33517. Epub 2021 Mar 19.
7
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
Clin Cancer Res. 2020 Aug 15;26(16):4206-4215. doi: 10.1158/1078-0432.CCR-19-4121. Epub 2020 May 22.
8
Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
Front Oncol. 2022 Jan 6;11:746571. doi: 10.3389/fonc.2021.746571. eCollection 2021.
9
Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Drug Resist Updat. 2016 Jan;24:55-69. doi: 10.1016/j.drup.2015.11.005. Epub 2015 Nov 26.
10
Niraparib for the treatment of ovarian cancer.
Expert Opin Pharmacother. 2017 Apr;18(6):631-640. doi: 10.1080/14656566.2017.1297423. Epub 2017 Apr 7.
引用本文的文献
1
Functional validation of somatic variability in and for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients.
Cancer Biol Ther. 2025 Dec;26(1):2543105. doi: 10.1080/15384047.2025.2543105. Epub 2025 Aug 10.
2
Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope.
Cells. 2025 Jun 29;14(13):995. doi: 10.3390/cells14130995.
3
Niraparib Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: Real-World Experience at Hospitals in Spain.
Target Oncol. 2025 Mar;20(2):319-327. doi: 10.1007/s11523-024-01121-5. Epub 2025 Jan 24.
4
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041.
5
Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.
Int J Mol Sci. 2023 Oct 11;24(20):15077. doi: 10.3390/ijms242015077.
6
Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer.
Front Oncol. 2023 Aug 22;13:1231460. doi: 10.3389/fonc.2023.1231460. eCollection 2023.
7
Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.
Int J Mol Sci. 2023 Jan 19;24(3):1973. doi: 10.3390/ijms24031973.
8
Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.
Life Sci Alliance. 2022 Oct 13;5(12):e202201551. doi: 10.26508/lsa.202201551.
本文引用的文献
1
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Ann Oncol. 2022 Oct;33(10):1021-1028. doi: 10.1016/j.annonc.2022.06.011. Epub 2022 Jun 27.
2
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6.
3
Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices.
ESMO Open. 2021 Jun;6(3):100135. doi: 10.1016/j.esmoop.2021.100135. Epub 2021 Apr 27.
4
PARPi after PARPi in epithelial ovarian cancer.
Gynecol Oncol Rep. 2021 Jan 11;35:100699. doi: 10.1016/j.gore.2021.100699. eCollection 2021 Feb.
5
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
Clin Cancer Res. 2020 Aug 15;26(16):4206-4215. doi: 10.1158/1078-0432.CCR-19-4121. Epub 2020 May 22.
6
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.
7
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Gynecol Oncol. 2020 Jan;156(1):38-44. doi: 10.1016/j.ygyno.2019.10.023. Epub 2019 Nov 4.
8
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
9
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19.
10
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1.
Zotero 插件